ADIMMUNE announced yesterday that it has completed the signing of the SMTA2 (Standard Material Transfer Agreement 2) under the PIP Framework (Pandemic Influenza Preparedness Framework) with the World Health Organization (WHO).
This agreement ensures that in the event of a pandemic outbreak of a novel influenza, vaccine and drug manufacturers who have signed the agreement can promptly obtain virus strains provided by the WHO and expedite the development of new influenza vaccines or antiviral drugs. By signing this agreement, ADIMMUNE is better equipped to assume the responsibility of vaccine development and supply to protect public safety during a pandemic outbreak.
ADIMMUNE has also committed to donating and supplying a substantial quantity of vaccines to the WHO after the development of new vaccines. Despite Taiwan not being a member state of the WHO, this agreement signed between ADIMMUNE, a Taiwanese local vaccine manufacturer, and the WHO signifies Taiwan's active participation in global pandemic prevention efforts. It also reflects the contribution of ADIMMUNE as a domestic vaccine manufacturer to Taiwan's pandemic diplomacy.
ADIMMUNE stated that the WHO, in response to pandemic influenza preparedness, has been selecting vaccine and drug manufacturers worldwide with production scale and export experience to ensure rapid access to vaccines in the event of an outbreak. Prior to this, 14 companies from Europe, the United States, and Asia have signed agreements with the WHO. ADIMMUNE is the first local manufacturer in Taiwan to sign such an agreement.
The focus of this agreement is to ensure that when a pandemic outbreak of novel influenza occurs, signatory manufacturers can promptly obtain PIP biological materials to initiate the development and production of new vaccines and drugs. Manufacturers also commit to donating or supplying new vaccines or drugs to the WHO at a certain proportion.
ADIMMUNE explained that since Taiwan is not a member state of the WHO, the signing of the agreement with the WHO went through prolonged negotiations to overcome various difficulties. This agreement not only enhances Taiwan's epidemic prevention capabilities during a pandemic but also fulfills the responsibility as a global epidemic prevention partner and establishes a cooperative relationship with the WHO.
ADIMMUNE joined the "International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Global Influenza Vaccine Supply Task Force" as early as 2012. It is a member of the alliance alongside 19 major global manufacturers supplying influenza vaccines such as Sanofi and GSK. Additionally, it is the only vaccine manufacturer from Taiwan to join the WHO's Pandemic Influenza Preparedness Framework (PIP Framework), providing unique advantages in responding rapidly to novel influenza outbreaks and supplying influenza vaccines.
Resource (Mandarin):
